Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis

NCT01194219 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

844

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Apremilast
DRUG: Placebo
DRUG: Topical treatments or phototherapy

Sponsor

Amgen